Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Cited by (1,000)

Items 501–600 of 1,000

1. The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between Mpro and antiviral drugs (nirmatrelvir and ritonavir)
   Ali Adel Dawood · 2022 · Advances in Medical Sciences
2. Multimeric ACE2-IgM fusions as broadly active antivirals that potently neutralize SARS-CoV-2 variants
   Hristo L. Svilenov, Romina Bester, Julia Sacherl, Ramona M. Absmeier, Carsten Peters, Ulrike Protzer, Carsten Brockmeyer, Johannes Büchner · 2022 · Communications Biology
3. Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens
   Sitthichai Kanokudom, Jira Chansaenroj, Nungruthai Suntronwong, Suvichada Assawakosri, Ritthideach Yorsaeng, Pornjarim Nilyanimit, Ratchadawan Aeemjinda, Nongkanok Khanarat, Preeyaporn Vichaiwattana, Sirapa Klinfueng et al. · 2022 · International Journal of Infectious Diseases
4. Immune responses related to the immunogenicity and reactogenicity of COVID-19 mRNA vaccines
   Takayuki Matsumura, Tomohiro Takano, Yoshimasa Takahashi · 2022 · International Immunology
5. Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities
   Mohammad Shah Alam · 2023 · Heliyon
6. Development of Next Generation Vaccines against SARS-CoV-2 and Variants of Concern
   Abdul Aziz Al-Fattah Bin Yahaya, Kanwal Khalid, Hui Xuan Lim, Chit Laa Poh · 2023 · Viruses
7. Specific pupylation as IDEntity reporter (SPIDER) for the identification of protein-biomolecule interactions
   He‐wei Jiang, Hong Chen, Yun-xiao Zheng, Xuening Wang, Qingfeng Meng, Jin Han Xie, Jiong Zhang, ChangSheng Zhang, Zhaowei Xu, Ziqing Chen et al. · 2023 · Science China Life Sciences
8. The XBB.1.5 slightly increase the binding affinity for host receptor ACE2 and exhibit strongest immune escaping features: molecular modeling and free energy calculation
   Muhammad Suleman, Aneela Murtaza, Maria, Haji Khan, Farooq Rashid, Abdulrahman Alshammari, Liaqat Ali, Abbas Khan, Dong‐Qing Wei · 2023 · Frontiers in Molecular Biosciences
9. COVID-19 pandemic sheds a new research spotlight on antiviral potential of essential oils – A bibliometric study
   Binawati Ginting, Williams Chiari, Teuku Fais Duta, Syihaabul Hudaa, Agnia Purnama, Harapan Harapan, Diva Rayyan Rizki, Kana Puspita, Rinaldi Idroes, Meriatna Meriatna et al. · 2023 · Heliyon
10. Safety and immunogenicity of Ad5-nCoV immunization after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults
    Hangjie Zhang, Nani Xu, Yu Song Xu, Pan Qin, Rongrong Dai, Bicheng Xu, Shenyu Wang, Linling Ding, Jian Fu, Shupeng Zhang et al. · 2023 · Nature Communications
11. A novel nanobody broadly neutralizes SARS‐CoV‐2 via induction of spike trimer dimers conformation
    Yang Yang, Junfang Zhang, Shengnan Zhang, Chenhui Zhang, Chenguang Shen, Shuo Song, Yanqun Wang, Yun Peng, Xiaohua Gong, Jun Dai et al. · 2023 · Exploration
12. Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants
    Lingyan Cui, Tingting Li, Wenhui Xue, Sibo Zhang, Hong Wang, Hongjing Liu, Ying Gu, Ningshao Xia, Shaowei Li · 2024 · Viruses
13. Spatial Engineering of Heterotypic Antigens on a DNA Framework for the Preparation of Mosaic Nanoparticle Vaccines with Enhanced Immune Activation against SARS‐CoV‐2 Variants
    Jialü Zhang, Yunyun Xu, Mingying Chen, Shengwen Wang, Guihong Lin, Yihao Huang, Chaoyong James Yang, Yang Yang, Yanling Song · 2024 · Angewandte Chemie International Edition
14. The Kinetics of SARS-CoV-2 Antibody Development Is Associated with Clearance of RNAemia
    Chuangqi Wang, Yijia Li, Paulina Kapłonek, Matteo Gentili, Stephanie Fischinger, Kathryn A. Bowman, Moshe Sade-Feldman, Kyle R. Kays, James Regan, James P. Flynn et al. · 2022 · mBio
15. Follow-up investigation and detailed mutational characterization of the SARS-CoV-2 Omicron variant lineages (BA.1, BA.2, BA.3 and BA.1.1)
    Qussai Abbas, Кусакин Алексей Викторович, Kinda Ali Sharrouf, Susan Jyakhwo, Aleksey S. Komissarov · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
16. ACE2-Targeting antibody suppresses SARS-CoV-2 Omicron and Delta variants
    Jianxia Ou, Yanan Zhang, Yongmei Wang, Zherui Zhang, Hongping Wei, Junping Yu, Qi Wang, Guifeng Wang, Bo Zhang, Chunhe Wang · 2022 · Signal Transduction and Targeted Therapy
17. Elucidating Design Principles for Engineering Cell‐Derived Vesicles to Inhibit SARS‐CoV‐2 Infection
    Taylor F. Gunnels, Devin M. Stranford, Roxana E. Mitrut, Neha P. Kamat, Joshua N. Leonard · 2022 · Small
18. Omicron-specific mRNA vaccine elicits potent immune responses in mice, hamsters, and nonhuman primates
    Yi Wu, Yanqiong Shen, Namei Wu, Xinghai Zhang, Shaohong Chen, Chang Wei Yang, Junhui Zhou, Yan Ling Wu, Da Chen, Li Wang et al. · 2022 · Cell Research
19. On the Origins of Omicron’s Unique Spike Gene Insertion
    AJ Venkatakrishnan, Praveen Anand, Patrick J. Lenehan, Rohit Suratekar, Bharathwaj Raghunathan, Michiel J.M. Niesen, Venky Soundararajan · 2022 · Vaccines
20. COVID-19 vaccine had a significant positive impact on patients with SARS-COV-2 during the third (Omicron) wave in Saudi Arabia
    Salma AlBahrani, Ali M. Albarrak, Tariq Al-Musawi, Nawal AlGubaisi, Maram Almalki, Fatimah Hassan Hakami, Turki Alghamdi, Zena AlBeiuruti, Sausan A. Alkhrashi, Meshael Musaed Almershad et al. · 2022 · Journal of Infection and Public Health
21. Systemic and T cell‐associated responses to SARS‐CoV ‐2 immunisation in gut inflammation ( STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS‐CoV ‐2
    Simon Woelfel, Joel Dütschler, Marius König, Nicole Graf, Vasileios Oikonomou, Claudia Krieger, Samuel Truniger, Annett Franke, Annika Eckhold, Kristina Forsch et al. · 2022 · Alimentary Pharmacology & Therapeutics
22. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants
    Xuejun Wang, Yao Lin, Hong-Yun Zhang, Ka-Li Zhu, Jing Zhao, Bingdong Zhan, Yike Li, Xue-Juan He, Cong Huang, Zhuang-Ye Wang et al. · 2022 · Genome Medicine
23. Neutralizing Efficacy of Encapsulin Nanoparticles against SARS-CoV2 Variants of Concern
    Sara Khaleeq, Nayanika Sengupta, Sahil Kumar, Unnatiben Rajeshbhai Patel, Raju Rajmani, Poorvi Reddy, Suman Pandey, Randhir Singh, Somnath Dutta, Rajesh P. Ringe et al. · 2023 · Viruses
24. Vaccination of SARS-CoV-2-infected individuals expands a broad range of clonally diverse affinity-matured B cell lineages
    M. Chernyshev, M. Sakharkar, R. Connor, H. Dugan, D. Sheward, C. G. Rappazzo, Aron Stålmarck, M. Forsell, Peter F. Wright, M. Corcoran et al. · 2023 · Nature Communications
25. Aptamer‐based strategies against SARS‐CoV‐2 viruses
    Yihao Huang, Ximing Chen, Jialü Zhang, Wenhai Tian, Siwen Liu, Rachel Chun‐Yee Tam, Chaoyong James Yang, Yanling Song · 2023 · BMEMat
26. Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial
    Lisa Seekircher, Zoltán Bánki, Janine Kimpel, Annika Rössler, Helena Schäfer, Barbara Falkensammer, David Bante, Lukas Forer, Sebastian Schönherr, Zoltán Bánki et al. · 2023 · The Lancet Microbe
27. Policies on children and schools during the SARS-CoV-2 pandemic in Western Europe
    Antoni Soriano‐Arandes, Ana Brett, Danilo Buonsenso, Louise Emilsson, Isabel de la Fuente Garcia, Despοina Gkentzi, Otto Helve, Kasper P. Kepp, Maria Mossberg, Taulant Muka et al. · 2023 · Frontiers in Public Health
28. Ursodeoxycholic Acid Does Not Improve COVID-19 Outcome in Hospitalized Patients
    Francesca Colapietro, Giovanni Angelotti, Chiara Masetti, Dana Shiffer, Nicola Pugliese, Stella De Nicola, Francesco Carella, Antonio Desai, Monica Ormas, Marta Calatroni et al. · 2023 · Viruses
29. Dynamical modelling of viral infection and cooperative immune protection in COVID-19 patients
    Zhengqing Zhou, Dianjie Li, Ziheng Zhao, Shuyu Shi, Jianghua Wu, Jianwei Li, Jingpeng Zhang, Ke Gui, Yu Long Zhang, Qi Ouyang et al. · 2023 · PLoS Computational Biology
30. Broad protective RBD heterotrimer vaccines neutralize SARS-CoV-2 including Omicron sub-variants XBB/BQ.1.1/BF.7
    Yanfang Zhang, Xinrui Kang, Sheng Liu, Pu Han, Wenwen Lei, Ke Xu, Zepeng Xu, Zhengrong Gao, Xuemei Zhou, Yuxuan Han et al. · 2023 · PLoS Pathogens
31. Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial
    Karine Lacombe, Thomas Hueso, Raphaël Porcher, Arsène MEKINIAN, Thibault Chiarabini, Sophie Georgin‐Lavialle, Florence Ader, Julien Saison, Guillaume Martin‐Blondel, Nathalie De Castro et al. · 2023 · BMJ Medicine
32. Assessing the Burden and Cost of COVID-19 Across Variants in Commercially Insured Immunocompromised Populations in the United States: Updated Results and Trends from the Ongoing EPOCH-US Study
    Amita Girish Ketkar, Vincent J. Willey, Lisa Glasser, Casey Dobie, Cachet Magdolna Wenziger, Chia‐Chen Teng, Christine Dube, Sunny Hirpara, Dennis J. Cunningham, Monica Verduzco‐Gutierrez · 2024 · Advances in Therapy
33. Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants
    Barbara Mühlemann, Jakob Trimpert, Felix Walper, Marie Luisa Schmidt, Jenny Jansen, Simon Schroeder, Lara Maria Jeworowski, Jörn Beheim-Schwarzbach, Tobias Bleicker, Daniela Niemeyer et al. · 2024 · Proceedings of the National Academy of Sciences
34. An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2
    Lianghui Zhang, Krishna K. Narayanan, Laura M. Cooper, Kui K. Chan, Christine A. Devlin, Aaron Aguhob, Kristie M. Shirley, Lijun Rong, Jalees Rehman, Asrar B. Malik et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
35. PPB-Affinity: Protein-Protein Binding Affinity dataset for AI-based protein drug discovery
    Huaqing Liu, Peiyi Chen, Xiaochen Zhai, Ku-Geng Huo, Shuxian Zhou, Lanqing Han, Guoxin Fan · 2024 · Scientific Data
36. Pre-existing neutralizing antibodies against cattle-transmitted influenza A virus H5N1 are detectable in unexposed individuals
    Katharina Daniel, Leon Ullrich, Denis Ruchnewitz, Matthijs Meijers, Nico Joël Halwe, Ursula Wild, Jan Eberhardt, Jacob Schön, Ricarda Stumpf, Maike Schlotz et al. · 2026 · Immunity
37. Omicron-included mutation-induced changes in epitopes of SARS-CoV-2 spike protein and effectiveness assessments of current antibodies
    Du Guo, Huaichuan Duan, Yan Cheng, Yueteng Wang, Jianping Hu, Hubing Shi · 2022 · Molecular Biomedicine
38. Single-Domain Antibodies as Therapeutics for Respiratory RNA Virus Infections
    Keke Huang, Tianlei Ying, Yanling Wu · 2022 · Viruses
39. Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses
    Qianqian Li, Li Zhang, Ziteng Liang, Nan Wang, Shuo Liu, Tao Li, Yuanling Yu, Qianqian Cui, Xi Wu, Jianhui Nie et al. · 2022 · Signal Transduction and Targeted Therapy
40. Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but not with Omicron BA.1.1 and BA.2 variants
    Sivaprakasam T. Selvavinayagam, Yean Kong Yong, Narcisse Mary Sither Joseph, Kannan Hemashree, Hong Yien Tan, Ying Zhang, Manivannan Rajeshkumar, Anandhazhvar Kumaresan, Raghu Kalpana, Vasudevan Kalaivani et al. · 2022 · Frontiers in Public Health
41. Predictors of Nonseroconversion to SARS-CoV-2 Vaccination in Kidney Transplant Recipients
    Sophie C. Frölke, Pim Bouwmans, A. Lianne Messchendorp, Suzanne E. Geerlings, Marc H. Hemmelder, Ron T. Gansevoort, Luuk B. Hilbrands, Marlies E. J. Reinders, Jan‐Stephan Sanders, Fréderike J. Bemelman et al. · 2022 · Transplantation Direct
42. Rapid Emergence of the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Korea
    Ae Kyung Park, Il‐Hwan Kim, Chae Young Lee, Jeong-Ah Kim, Hyeokjin Lee, Heui Man Kim, Nam‐Joo Lee, SangHee Woo, Jaehee Lee, Jee Eun Rhee et al. · 2022 · Annals of Laboratory Medicine
43. Broadly neutralizing aptamers to SARS-CoV-2: A diverse panel of modified DNA antiviral agents
    Amy D. Gelinas, Tiong Kit Tan, Sai Liu, Javier Gilbert‐Jaramillo, James Chadwick, Adam C. Harding, Chi Zhang, Brian E. Ream, Chelsea N. Chase, Matthew R. Otis et al. · 2023 · Molecular Therapy — Nucleic Acids
44. Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters
    María Rescigno, Chiara Agrati, Carlo Salvarani, Diana Giannarelli, Massimo Costantini, Alberto Mantovani, Raffaella Massafra, Pier Luigi Zinzani, Aldo Morrone, Stefania Notari et al. · 2023 · Frontiers in Immunology
45. Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial
    Huijie Bian, Liang Chen, Zhaohui Zheng, Xiuxuan Sun, Jiejie Geng, Ruo Chen, Ke Wang, Xu Yang, Shirui Chen, Siyu Chen et al. · 2023 · Signal Transduction and Targeted Therapy
46. Incidence and Predictors of Breakthrough and Severe Breakthrough Infections of SARS-CoV-2 After Primary Series Vaccination in Adults: A Population-Based Survey of 22 575 Participants
    Stacia M. DeSantis, Ashraf S. Yaseen, Tianyao Hao, Luis León‐Novelo, Yashar Talebi, Melissa A. Valerio-Shewmaker, Cesar Leonardo Pinzon-Gomez, Sarah Elizabeth Messiah, Harold Willis Kohl, Steven Harold Kelder et al. · 2023 · The Journal of Infectious Diseases
47. Evolution of Immune Evasion and Host Range Expansion by the SARS-CoV-2 B.1.1.529 (Omicron) Variant
    Wenlin Ren, Yu Zhang, Juhong Rao, Ziyi Wang, Jun Lan, Kunpeng Liu, Xuekai Zhang, Xue Hu, Chen Yang, Guocai Zhong et al. · 2023 · mBio
48. Post-exposure prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray for the prevention of symptomatic COVID-19 in healthy adult workers: a randomized, single-blind, placebo-controlled clinical study
    Rui Song, Gang Zeng, Jianxing Yu, Xing Meng, Xiaoyou Chen, Jing Li, Xiaoliang Sunney Xie, Xiaojuan Lian, Zhiyun Zhang, Yunlong Cao et al. · 2023 · Emerging Microbes & Infections
49. Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies
    Fengwen Zhang, Jesse Jenkins, Robson Amparo de Carvalho, Sandra Nakandakari-Higa, Teresia Chen, Morgan E. Abernathy, Viren A. Baharani, Elisabeth K. Nyakatura, David P. Andrew, Irina V. Lebedeva et al. · 2023 · Nature Microbiology
50. Structural and computational design of a SARS-CoV-2 spike antigen with improved expression and immunogenicity
    James A. Williams, Marco Biancucci, Laura N. Lessen, Sai Tian, Ankita Balsaraf, Lynn Chen, Chelsy C. Chesterman, Giulietta Maruggi, Sarah Vandepaer, Ying Huang et al. · 2023 · Science Advances
51. Positively Charged-Amylose-Entangled Au-Nanoparticles Acting as Protein Carriers and Potential Adjuvants to SARS-CoV-2 Subunit Vaccines
    Baochao Fan, Jun Gu, Bin Deng, Weilu Guo, Shuaifeng Zhang, Li Li, Bin Li · 2023 · ACS Applied Materials & Interfaces
52. Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants
    Cheng‐Pu Sun, Chi-Wen Chiu, Ping‐Yi Wu, Szu-I Tsung, I‐Jung Lee, Chih-Wei Hu, Min‐Feng Hsu, Tzu-Jiun Kuo, Yu-Hua Lan, Li-Yao Chen et al. · 2023 · Molecular Therapy
53. Review: The Landscape of Antiviral Therapy for COVID-19 in the Era of Widespread Population Immunity and Omicron-Lineage Viruses
    Eric Allan Meyerowitz, Yijia Li · 2023 · Clinical Infectious Diseases
54. Divergent trajectory of replication and intrinsic pathogenicity of SARS-CoV-2 Omicron post-BA.2/5 subvariants in the upper and lower respiratory tract
    Bingjie Hu, Jasper Fuk‐Woo Chan, Yuanchen Liu, Huan Liu, Yanxia Chen, Huiping Shuai, Ye‐Fan Hu, Madeline Hartnoll, Li Chen, Yao Xia et al. · 2023 · EBioMedicine
55. Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain
    Rajeshwer Singh Sankhala, Vincent Dussupt, Wei‐Hung Chen, Hongjun Bai, Elizabeth J. Martinez, Jaime L. Jensen, Phyllis A. Rees, Agnes Hajduczki, William C. Chang, Misook Choe et al. · 2023 · Structure
56. Advancing Antibody Engineering through Synthetic Evolution and Machine Learning
    Edward B. Irvine, Sai T. Reddy · 2024 · The Journal of Immunology
57. Identification of a broad sarbecovirus neutralizing antibody targeting a conserved epitope on the receptor-binding domain
    Yanqun Wang, Zhaoyong Zhang, Minnan Yang, Xinyi Xiong, Qihong Yan, Lei Cao, Peilan Wei, Yuting Zhang, Lu Zhang, Kexin Lv et al. · 2024 · Cell Reports
58. Factors Predicting COVID-19 Vaccine Effectiveness and Longevity of Humoral Immune Responses
    Engin Berber, Ted M. Ross · 2024 · Vaccines
59. Evidence of elusive Majorana particle dies — but computing hope lives on
    Davide Castelvecchi · 2021 · Nature
60. Can the SARS-CoV-2 Omicron Variant Confer Natural Immunity against COVID-19?
    Abdul Hawil Abas, Siti Marfuah, Rinaldi Idroes, Diah Kusumawaty, Fatimawali Fatimawali, Moon Nyeo Park, Abolghasem Siyadatpanah, Fahad Abdulrahman Alhumaydhi, Shafi Mahmud, Trina Ekawati Tallei et al. · 2022 · Molecules
61. Why Controlling the Asymptomatic Infection Is Important: A Modelling Study with Stability and Sensitivity Analysis
    Jiaji Pan, Zhongxiang Chen, Yixuan He, Tongliang Liu, Xi Cheng, Jun Xiao, Hao Feng · 2022 · Fractal and Fractional
62. Cocktail of REGN Antibodies Binds More Strongly to SARS-CoV-2 Than Its Components, but the Omicron Variant Reduces Its Neutralizing Ability
    Hung Van Nguyen, Pham Dang Lan, Daniel Allen Nissley, Edward P. O’Brien, Mai Suan Li · 2022 · The Journal of Physical Chemistry B
63. Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model
    Dylan M. Johnson, Trevor Brasel, Shane Massey, Tania M. Garron, Michael Grimes, Jeanon N. Smith, Maricela Torres, Shannon M. Wallace, Alejandro G. Villasante Tezanos, David W. C. Beasley et al. · 2022 · Antiviral Research
64. Structural and computational insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction
    Jun Lan, Xinheng He, Yifei Ren, Ziyi Wang, Huan Zhou, Shilong Fan, Chenyou Zhu, Dongsheng Liu, Bin Shao, Tie‐Yan Liu et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
65. Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins
    Zi-Jun Wang, Frauke Muecksch, Alice Cho, C. Gaebler, H. Hoffmann, Victor A. Ramos, Shuaizhou Zong, M. Cipolla, Bryant Johnson, Fabian Schmidt et al. · 2022 · bioRxiv
66. Ultrapotent class I neutralizing antibodies post Omicron breakthrough infection overcome broad SARS-CoV-2 escape variants
    Mengxiao Luo, Runhong Zhou, Bingjie Tang, Hang Liu, Bo‐Hao Chen, Na Liu, Yufei Mo, Pengfei Zhang, Ye Lim Lee, Jonathan Daniel Ip et al. · 2024 · EBioMedicine
67. A spike protein S2 antibody efficiently neutralizes the Omicron variant
    Jia Hu, Xiang Chen, Xingbing Lu, Lijuan Wu, Liyuan Yin, Lingling Zhu, Hao Liang, Feng Xu, Qinghua Zhou · 2022 · Cellular and Molecular Immunology
68. Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization
    Haijun Tang, Long Gao, Zhao Wu, Fang Meng, Xin Zhao, Yun Shao, Guocun Hou, Xiaohong Du, Frank Xiao-Feng Qin · 2022 · Frontiers in Immunology
69. The nervous system during COVID ‐19: Caught in the crossfire
    Nick R. Natale, John R. Lukens, William A. Petri · 2022 · Immunological Reviews
70. Clinical Characteristics of Omicron SARS-CoV-2 Variant Infection After Non-mRNA-Based Vaccination in China
    Qing‐Lei Zeng, Yuanjun Lv, Xiaojing Liu, Zhi-Yong Jiang, Shuo Huang, Wei-Zhe Li, Zujiang Yu · 2022 · Frontiers in Microbiology
71. Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022
    Juan Li, Rui Song, Zheng Yuan, Zheng Xu, Luodan Suo, Qing Wang, Yuan Li, Yanlin L. Gao, Xiaomei Li, Xiaoyou Chen et al. · 2022 · Vaccines
72. Modelling optimal lockdowns with waning immunity
    Aditya Goenka, Lin Liu, Manh‐Hung Nguyen · 2022 · Economic Theory
73. Comparative Binding Ability of Human Monoclonal Antibodies against Omicron Variants of SARS-CoV-2: An In Silico Investigation
    N. Das, P. Chakraborty, J. Bayry, Suprabhat Mukherjee · 2023 · Antibodies
74. Comprehensive structural analysis reveals broad-spectrum neutralizing antibodies against SARS-CoV-2 Omicron variants
    Xiangyang Chi, Lingyun Xia, Guanying Zhang, Ximin Chi, Bangdong Huang, Yuanyuan Zhang, Zhengshan Chen, Jin Han, Liushu Wu, Zeya Li et al. · 2023 · Cell Discovery
75. A nanobody recognizes a unique conserved epitope and potently neutralizes SARS-CoV-2 omicron variants
    Naphak Modhiran, Simon Malte Lauer, Alberto Anastacio Amarilla, Peter Hewins, Sara Lopes van den Broek, Yu Shang Low, Nazia Thakur, Benjamin Liang, Guillermo Valenzuela, James Jung et al. · 2023 · iScience
76. New Viral Diseases and New Possible Remedies by Means of the Pharmacology of the Renin-Angiotensin System
    Giovanni G. Sansoe, Manuela Aragno · 2023 · Journal of the Renin-Angiotensin-Aldosterone System
77. Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern
    Ryan P. McNamara, Jenny S. Maron, Julie Boucau, Vicky Roy, Nicholas E. Webb, Harry L. Bertera, Amy K. Barczak, The Staff, Nicholas Franko, Jennifer K. Logue et al. · 2023 · mBio
78. Investigation of the Host Kinome Response to Coronavirus Infection Reveals PI3K/mTOR Inhibitors as Betacoronavirus Antivirals
    Ethan J. Fritch, Angie L. Mordant, Thomas S.K. Gilbert, Carrow I. Wells, Xuan Yang, Natalie K. Barker, Emily A. Madden, Kenneth H. Dinnon, Yixuan Jacob Hou, Longping V. Tse et al. · 2023 · Journal of Proteome Research
79. Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022
    Victoria Jane Hall, Ferdinando Insalata, Sarah Foulkes, Peter Kirwan, Dominic Sparkes, Ana Atti, Michelle Jayne Cole, Elen De Lacy, Lesley Price, Diane Corrigan et al. · 2023 · Journal of Infection
80. Semisynthesis of homogeneous spike RBD glycoforms from SARS-CoV-2 for profiling the correlations between glycan composition and function
    Farong Ye, Cheng Li, Feng‐Liang Liu, Xinliang Liu, Peng Hui Xu, Rong‐Hua Luo, Wenping Song, Yong‐Tang Zheng, Tianlei Ying, Biao Yu et al. · 2024 · National Science Review
81. Evasion of NKG2D-mediated cytotoxic immunity by sarbecoviruses
    Jordan A. Hartmann, Marcella Regina Cardoso, Maria Cecília Ramiro Talarico, Devin Kenney, Madison R. Leone, Dagny C. Reese, Jacquelyn Turcinovic, Aoife Kateri O’Connell, Hans P. Gertje, Caitlin Marino et al. · 2024 · Cell
82. EpiScan: accurate high-throughput mapping of antibody-specific epitopes using sequence information
    Chuan Wang, Jiangyuan Wang, Wenjun Song, Guan‐Zheng Luo, Taijiao Jiang · 2024 · npj Systems Biology and Applications
83. Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and Implementation
    K. van der Straten, M. V. van Gils, S. D. de Taeye, G. D. de Bree · 2022 · Frontiers in Medical Technology
84. SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses
    Masaud Shah, Sung Ung Moon, Jang Hyun Kim, Trinh Thanh Thao, Hyun Goo Woo · 2022 · Computational and Structural Biotechnology Journal
85. Quantitative and Qualitative Difference in Antibody Response against Omicron and Ancestral SARS-CoV-2 after Third and Fourth Vaccination
    Sascha Hein, Ines Mhedhbi, Tobias R. Zahn, Catarina Sabino, Nuka Ivalu Benz, Younes Husria, Patricia Maria Renelt, Floriane C. M. Braun, Doris Oberle, Thorsten J. Maier et al. · 2022 · Vaccines
86. Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis
    Christine M. Bestvina, Jennifer G. Whisenant, Valter Torri, Alessio Cortellini, Heather A. Wakelee, Solange Peters, Elisa Roca, Alessandro De Toma, Fred R. Hirsch, Hirva Mansurali Mamdani et al. · 2022 · JTO Clinical and Research Reports
87. A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity
    Peng Fei Du, Ning Li, Xinxin Xiong, Shengjun Tang, Qinjin Dai, Zhihai Liu, Taorui Wang, Xueping Gu, Zhongcheng Zhou · 2022 · Journal of Medical Virology
88. Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants
    Daniel Junker, Matthias Becker, Teresa R. Wagner, Philipp D. Kaiser, Sandra M. Maier, Tanja M. Grimm, Johanna Griesbaum, Patrick Marsall, Jens Gruber, Bjoern Traenkle et al. · 2022 · Clinical Infectious Diseases
89. Production of a versatile SARS‐CoV‐2 main protease biosensor based on a dimerization‐dependent red fluorescent protein
    Haohao Yan, Rui Zhang, Gangan Yan, Zhicheng Liu, Xiaoli Liu, Xiaoping Liu, Yunyu Chen · 2022 · Journal of Medical Virology
90. Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants
    Sylvia Rothenberger, Daniel L. Hurdiss, Marcel Walser, Francesca Malvezzi, Jennifer Mayor, Sarah Ryter, Héctor Moreno, Nicole Liechti, Andreas Bosshart, Chloé Iss et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
91. Reduced sera neutralization to Omicron SARS-CoV-2 by both inactivated and protein subunit vaccines and the convalescents
    Xin Zhao, Dedong Li, Wenjing Ruan, Rong Zhang, Anqi Zheng, Shitong Qiao, Xinlei Zheng, Yingze Zhao, Zhihai Chen, Lianpan Dai et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
92. Predicting pathogen evolution and immune evasion in the age of artificial intelligence
    David J. Hamelin, Matthew Scicluna, I Saadie, Fatima Mostefai, Jean‐Christophe Grenier, Cantin Baron, Étienne Caron, Julie Hussin · 2025 · Computational and Structural Biotechnology Journal
93. Evidence-based dosing of convalescent plasma for COVID-19 in future trials
    Bart J. A. Rijnders, Sammy Huygens, Jordi Mitjà · 2022 · Clinical Microbiology and Infection
94. Assessment of the Abbott BinaxNOW SARS-CoV-2 rapid antigen test against viral variants of concern
    Anuradha Rao, Leda Bassit, Jessica Lin, Kiran Verma, Heather B. Bowers, Kimberly J. Pachura, Morgan N. Greenleaf, Julie A. Sullivan, Eric Lai, Richard S. Creager et al. · 2022 · iScience
95. Broadly Neutralizing Antibodies to SARS-CoV-2 Provide Novel Insights Into the Neutralization of Variants and Other Human Coronaviruses
    Prashant Bajpai, Vanshika Singh, Anmol Chandele, Sanjeev Kumar · 2022 · Frontiers in Cellular and Infection Microbiology
96. Durability analysis of the highly effective BNT162b2 vaccine against COVID-19
    Arjun Puranik, Patrick J. Lenehan, John Charles O’Horo, Colin Pawlowski, Michiel J.M. Niesen, Abinash Virk, Melanie D. Swift, Walter K. Kremers, AJ Venkatakrishnan, Joel E. Gordon et al. · 2022 · PNAS Nexus
97. Structures of the SARS-CoV-2 spike glycoprotein and applications for novel drug development
    Xiao-Huan Liu, Ting Cheng, Baoyu Liu, Jia Chi, Ting Shu, Tao Wang · 2022 · Frontiers in Pharmacology
98. A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery
    Xinghai Zhang, Huajun Zhang, Tingting Li, Shaohong Chen, Feiyang Luo, Junhui Zhou, Peiyi Zheng, Shuyi Song, Yan Wu, Tengchuan Jin et al. · 2022 · Signal Transduction and Targeted Therapy
99. Localized delivery of nanomedicine and antibodies for combating COVID-19
    Bin Tu, Yanrong Gao, Xinran An, Huiyuan Wang, Yongzhuo Huang · 2022 · Acta Pharmaceutica Sinica B
100. Amphiphile-CpG vaccination induces potent lymph node activation and COVID-19 immunity in mice and non-human primates
     Lochana M. Seenappa, Aniela Jakubowski, Martin Peter Steinbuck, Erica Palmer, Christopher M. Haqq, Crystal Carter, Jane A. Fontenot, Francois J. Villinger, Lisa Kristin McNeil, Peter C. DeMuth · 2022 · npj Vaccines